Article
Document
Information Content Entity
Academic Article
RDF description of Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis? - http://irises.unisr.it/resource/item/98953
Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?
Generically Dependent Continuant